Amgen Inc

Industry: Biotechnology Drugs

Fortune Rank: 159

For the nine months ended 30 September 2005, Amgen, Inc.'s revenues rose 20% to $9.16B. Net income rose 70% to $2.85B. Revenues reflect higher demand for Aranesp(R), ENBREL(R) and Neulasta(R). Net income benefited from decreased selling, general & administrative expenses as a percentage of revenues and the absence of write-off of acquired in-process research & development expenses. The Company is engaged in manufacturing of human therapeutics.

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. It operates in one business segment: human therapeutics. Amgen markets human therapeutic products in the areas of nephrology, supportive cancer care and inflammatory disease. Its principal products include EPOGEN (Epoetin alfa), Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and ENBREL (etanercept), which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. Amgen markets its products to healthcare providers, including clinics, hospitals and pharmacies. The Company operates in the United States, Europe, Canada and Australia. On August 13, 2004, Amgen acquired Tularik Inc. (Tularik). Tularik was a company engaged in drug discovery related to cell signaling and the control of gene expression.

Amgen Inc

Amgen Inc is a Fortune 500 company. In 2010 Amgen Inc was ranked number 159 on the Fortune 500 list, making it the 159th largest company in the United States when judged by revenue.

Amgen Inc achieved revenue of $14,642.00 million in 2010 and earned a profit of $4,605.00 million.

Amgen Inc' rank improves

The company ranking improved in 2010, moving up the Fortune 500 list to 159th compared to 168th in 2009. This was based on its 2009 revenue of $15,003 million (a change of -1 million compared to 2010) and profits of $4,196 million (a change of $0 million compared to 2009).

Another point of view

To many investors, profits are more important than the revenue a company earns. If the Fortune 500 was ranked by profits instead of revenue then Amgen Inc would be ranked 30th rather than 159th due to its profits of $4,605 in 2010.

Amgen Inc Revenue* Profit* Fortune Ranking

* US$ Million

USPages Latest Business News At A Glance Business Shortcuts